Business Context and Reporting Period
This Form 8-K filing by Alnylam Pharmaceuticals, Inc. covers events occurring on January 6, 2018, and January 7, 2018. The report details a strategic restructuring of the company's collaboration with Genzyme Corporation and provides updated financial guidance regarding cash positions.
Key Financial Metrics and Agreements
- Cash Position: The company updated its guidance to expect ending 2017 with greater than $1.7 billion in cash, cash equivalents, marketable securities, and restricted cash.
- Milestone Payment: Genzyme is obligated to pay Alnylam a one-time milestone of $50.0 million upon the dosing of the first patient in the ATLAS Phase 3 program for ALN-AT3 (fitusiran).
- Royalty Structure:
- Alnylam will receive tiered royalties of 15% to 30% on global net sales of ALN-AT3 (fitusiran) and up to 15% on back-up products.
- Genzyme will receive royalties up to 25% (increasing over time) on ALN-TTR02 (patisiran) sales outside the U.S., Canada, and Western Europe, with a fixed 25% rate for Japan.
- Genzyme will receive tiered royalties of 15% to 30% on global net sales of ALN-TTRsc02.
Material Changes Versus Prior Period
The filing reports a significant shift in development and commercialization responsibilities under the amended Master Collaboration Agreement:
- ALN-TTR02 (patisiran) and ALN-TTRsc02: Alnylam now holds the exclusive right to pursue global development and commercialization. Alnylam will fund all associated costs.
- ALN-AT3 (fitusiran): Genzyme now holds the exclusive right to pursue global development and commercialization. Alnylam will fund costs only through a transition period up to a specified cap, after which Genzyme assumes full funding responsibility.
- Termination of Co-development: Previous co-development and co-commercialization rights for ALN-TTRsc, ALN-TTRsc02, and ALN-AT3 have been terminated.
Guidance, Outlook, and Risks
- Outlook: The company announced pipeline goals for 2018 and reaffirmed its advancement toward the "Alnylam 2020" guidance.
- Risks and Contingencies: The transaction is subject to customary closing conditions and regulatory clearances, specifically under the Hart-Scott-Rodino Antitrust Improvements Act.
- Future Rights: Genzyme retains the right to opt into Alnylam's other rare genetic disease programs for territories outside the U.S., Canada, and Western Europe, plus one right to a global license.
Investor Verification Checklist
- Verify the exact date of the first patient dosing in the ATLAS Phase 3 program to confirm the trigger for the $50.0 million milestone payment.
- Monitor the status of Hart-Scott-Rodino Antitrust clearance to ensure the transaction closes as expected.
- Review the upcoming Form 10-Q for the quarter ended March 31, 2018, for the full text of the Collaboration Amendment, AT3 License Terms, and Exclusive TTR License.
- Confirm the specific "specified cap" for Alnylam's funding of ALN-AT3 development during the transition period, as the exact dollar amount is not detailed in this filing.